A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates
Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight'
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
Medtronic steps up with up to $585M deal for Israeli devicemaker CathWorks
FDA demands better response from Abbott over Libre inspection violations
FDA demands better response from Abbott over Libre inspection violations
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq
Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
Hims & Hers to sell Grail’s Galleri multi-cancer blood test via its digital health platform
NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable
NHS 'FIT' bowel cancer test reduced unnecessary referrals as cancer numbers remain stable
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1
Amgen advances toward lupus redemption while gastric cancer candidate struggles
Amgen advances toward lupus redemption while gastric cancer candidate struggles
HHS launches $100M antiviral prize to develop broad-spectrum therapies
HHS launches $100M antiviral prize to develop broad-spectrum therapies
NIH turmoil takes center stage as director acknowledges no vaccine-autism link
NIH turmoil takes center stage as director acknowledges no vaccine-autism link
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases
Charles River to close cell therapy CDMO site, lay off 20 staffers
Charles River to close cell therapy CDMO site, lay off 20 staffers
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b
NMD flunks rare disease trial but flexes secondary data to accelerate program
NMD flunks rare disease trial but flexes secondary data to accelerate program
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page